What therapeutic areas does AILEX PHARMS LLC focus on?

AILEX PHARMS LLC focuses primarily on Cardiovascular.

Data updated: Jun 28, 2026

AILEX PHARMS LLC

Q: What drugs does AILEX PHARMS LLC make?

AILEX PHARMS LLC has 3 FDA-approved drugs including BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, SODIUM PHENYLACETATE AND SODIUM BENZOATE.

Generics

Cardiovascular

AILEX PHARMS LLC is a generic drug manufacturer focused on Cardiovascular. Key products include SODIUM PHENYLACETATE AND SODIUM BENZOATE.

2016

Since

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

AILEX PHARMS LLC's Key Drugs

AILEX PHARMS LLC's core commercial portfolio centers on BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE, SODIUM PHENYLACETATE AND SODIUM BENZOATE, spanning Cardiovascular — its most strategically important drugs approved in the last 15 years.

BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE

Gastrointestinal

Traveler's Diarrhea

Approved 2018

SODIUM PHENYLACETATE AND SODIUM BENZOATE

Rare Disease

Hyperammonemia

Approved 2016

AILEX PHARMS LLC's Recent FDA Approvals

New NDA/BLA approvals for AILEX PHARMS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AILEX PHARMS LLC's Therapeutic Areas

AILEX PHARMS LLC's approved drugs and pipeline span 1 therapeutic area, led by Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 100%

1 drugs

AILEX PHARMS LLC's Top Competitors

AILEX PHARMS LLC's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.